Participants joined to explore the rapidly growing world of Advanced Therapy Medicinal Products (ATMPs), a sector projected to be worth $22.80 billion by 2032. ATMPs represented a revolutionary shift in the approach to treatment, with Big Pharma heavily investing in dedicated facilities worldwide. However, building an ATMP facility involved navigating unique challenges that demanded a fresh approach.
Attendees signed up to discover what made ATMPs so special, the hurdles they presented, and why standard facility designs wouldn’t suffice.
In an industry as dynamic and regulated as pharmaceutical manufacturing, staying ahead of the curve proved crucial for success. This webinar provided an overview of trending tools and practices shown to be effective.
- There was a discussion on what made ATMPs unique in terms of manufacturing processes, the manufacturing facility, and logistics.
- The specific challenges ATMPs presented in development and manufacturing were also discussed. Participants delved into the distinct challenges posed by ATMPs in the pharmaceutical industry, gaining an understanding of the complexities involved in developing and manufacturing these innovative therapies. They explored the stringent regulatory requirements, high costs, and logistical hurdles that companies had to overcome to bring these therapies to market.
- An explanation was provided on why standard facility considerations for other therapies did not apply to ATMPs.
- An interactive Q&A session allowed participants to delve into the intricacies of ATMPs. A panel of experts addressed pressing questions on the development, production, and regulatory aspects of ATMPs.
